Study Assessing the Efficacy of Eductyl® for the Treatment of Patients With Dyschesia

Inclusion Criteria: * Male or female aged from 18 to 75 years old, * Writing consent to take part in the study, * Patient with a dyschesia according to Rome III criteria * An intensity of the inconfort using a VAS (0 (no inconfort) to 100 mm (maximal and no supportable inconfort)) equal or over 40 mm Exclusion Criteria: * Patient suffering of neurologic affection, * Rectal diseases including : * Current anal ou peri-anal pain, * Current organic injury of colon or rectum, * Current anal injury, * Current rectal Prolapse, * Current haemorrhoid, * Colon inflammatory disease (ulcero haemorrhagic recto colitis, Crohn disease…), * Current ano-recto-colon stenosis (anastomosis, scarring ...) * Patient undergone pain killers (WHO level II (except dextropropoxyphen) and III) during the last 8 days, * Patient undergone anti-depressants except if this treatment is regular for at least 15 days and it won't be modified during the study, * Patient with a constipation treatment except if this treatment is regular for at least 15 days and it won't be modified during the study * Intolerance to Eductyl® or to one of its components (potassium tartarate acid, sodium bicarbonate, solid hemisynthethic glycerides, soya lecithin, talc) * Use of Eductyl® during the previous 15 days (over 5 days in the last 15 days), * Patient already included in clinical trial in the last month, * Pregnant or breast feeding woman, * Woman of childbearing potential without contraception, * Patient unable to read and write.